

HLS Therapeutics Reports Annual Meeting Results

TORONTO, ON – June 19, 2020 – HLS Therapeutics Inc. (“HLS” or the “Company”) (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held on June 19, 2020 in Toronto, Ontario.

A total of 29,525,760 Common Shares, or 93.02% of the total Common Shares issued and outstanding, were voted by proxy at the meeting. Each director nominee was elected by a show of hands. Based on proxies received prior to the meeting, voting by individual director was as follows:

Nominees	Votes For	% For	Votes Withheld	% Withheld
William Wells	28,291,936	99.27%	206,852	0.73%
Greg Gubitz	28,498,068	100.00%	720	0.00%
J. Spencer Lanthier	28,261,795	99.17%	236,993	0.83%
Yvon Bastien	27,371,459	96.04%	1,127,329	3.96%
Rodney Hill	28,264,295	99.18%	234,493	0.82%
Don DeGolyer	28,262,859	99.17%	235,929	0.83%
Laura Brege	28,294,338	99.28%	204,450	0.72%

Shareholders also voted in favour of the re-appointment of Ernst & Young LLP as HLS’s auditors.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS’s focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS’s management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com

HLS CONTACT INFORMATION

Dave Mason
Investor Relations
HLS Therapeutics Inc.
(416) 247-9652
dave.mason@loderockadvisors.com

Gilbert Godin
President and Chief Operating Officer
HLS Therapeutics Inc.
(484) 232-3400 ext101
g.godin@hlstherapeutics.com